	US 12,291,578 B2
	Anti-matrix metalloproteinase 7 (MMP-7) inhibitory antibody and uses thereof
Irit Sagi, Rehovot (IL); and Vishnu Mohan, Rehovot (IL)
Assigned to Yeda Research and Development Co. Ltd., Rehovot (IL)
Appl. No. 17/429,672
Filed by Yeda Research and Development Co. Ltd., Rehovot (IL)
PCT Filed Feb. 10, 2020, PCT No. PCT/IL2020/050158 § 371(c)(1), (2) Date Aug. 10, 2021, PCT Pub. No. WO2020/161724, PCT Pub. Date Aug. 13, 2020.
Claims priority of application No. 264768 (IL), filed on Feb. 10, 2019.
Prior Publication US 2022/0106405 A1, Apr. 7, 2022
Int. Cl. C07K 16/40 (2006.01); A61K 31/282 (2006.01); A61K 31/7068 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01)

CPC C07K 16/40 (2013.01) [A61K 31/282 (2013.01); A61K 31/7068 (2013.01); A61K 39/00 (2013.01); A61P 35/00 (2018.01); C07K 16/303 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

17 Claims

1. A method of treating a disease associated with imbalanced or abnormal activity of MMP-7 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody, having complementarity determining region amino acid sequences as set forth in: SEQ ID NOs: 3, 4 and 5, sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6 , 7 and 8, sequentially arranged from N to C on a heavy chain of the antibody, thereby treating the disease associate with imbalanced or abnormal activity of MMP-7 in the subject.